Vantia Therapeutics appoints new chief executive

Andrew Crockett wins promotion after 12 months with pharma company

Vantia Therapeutics has appointed Andrew Crockett to the position of chief executive.

Since joining the Southampton, UK-based emerging pharmaceutical firm in 2009 as vice president of business development, Crockett has made a significant contribution to Vantia’s corporate development. He was previously with US specialist pharma company ZARS Pharma.

Martin Murphy, non-executive chairman of Vantia, said: ‘We are very pleased that Andrew Crockett has accepted the position as ceo. Vantia has made considerable progress over the past two years in advancing its pipeline of novel small molecule drug candidates into Phase II clinical trials. We wish Jim Phillips, the former ceo, well and appreciate his contribution to the team. The management team has created a solid platform for Vantia and we are therefore very pleased that Andrew will continue the great work that has been started.’

Crockett added: ‘We are looking forward to an exciting second half of the year when we expect important clinical data from our Phase IIa efficacy study in dysmenorrhoea and from our Phase IIb study in nocturia.’

Vantia Therapeutics develops novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research’s small molecule r&d, it has two clinical phase products, VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation.

You may also like

Research & Development

Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells

Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development

EVerZom and GENFIT partner for research collaboration for liver failure candidate EViv

The agreement will support EVerZom’s dynamic development strategy and follows the recent announcement of a €10m financing round aimed at accelerating its clinical and partnering roadmap
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Sustainability

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti
Ingredients

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification
Ingredients

Flowchem teaching manual now available to download

Guide offers step-by-step instructions for ten reactions including Nobel Prize-winning examples
Research & Development

EazeBio and UC Santa Cruz partner to launch instrument-free diagnostic platform for global health

The pair will co-develop a lab-independent cortisol biosensor, delivering rapid, affordable and AI-guided diagnostics for stress, metabolic health and a range of global health applications
Subscribe now